SAN DIEGO, July 10, 2018 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (NASDAQ: NBIX) announced today that it will
report second quarter financial results after the Nasdaq market
closes on Tuesday, July 31, 2018.
Neurocrine will then host a conference call and webcast to discuss
its financial results and provide a Company update that day at
1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
Participants can access the live conference call by dialing
877-876-9177 (US) or 785-424-1669 (International) using the
conference ID: NBIX. The webcast can also be accessed on
Neurocrine's website under Investors at http://www.neurocrine.com.
A replay of the webcast will be available on the website
approximately one hour after the conclusion of the event and will
be archived for one month.
About Neurocrine Biosciences, Inc.
Neurocrine
Biosciences is a San Diego based biotechnology
company focused on neurological and endocrine related disorders.
The Company markets INGREZZA® (valbenazine)
capsules in the United States for the treatment of adults
with tardive dyskinesia. INGREZZA is a novel, selective
vesicular monoamine transporter 2 (VMAT2) inhibitor, and is the
first FDA approved product indicated for the treatment of
adults with tardive dyskinesia. The Company's three late-stage
clinical programs are: elagolix, a gonadotropin-releasing hormone
antagonist for women's health that is partnered with AbbVie
Inc.; opicapone, a novel, once-daily, peripherally-acting,
highly-selective catechol-o-methyltransferase inhibitor under
investigation as adjunct therapy to levodopa in Parkinson's
patients; and INGREZZA, a novel, once-daily, selective VMAT2
inhibitor under investigation for the treatment of Tourette
syndrome.
Neurocrine Biosciences, Inc. news releases are available
through the Company's website via the internet
at http://www.neurocrine.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2018-financial-results-300678818.html
SOURCE Neurocrine Biosciences, Inc.